In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that ...

The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance ...

CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic ...

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...

The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

Pillar Biosciences today announced the launch of the oncoReveal® Rapid AML Panel, a focused research-use-only (RUO) DNA ...

CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...

While not every patient with AML develops skin involvement, it can be one of the earliest visible signs that something systemic is occurring.

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

Fred Hutch Cancer Center hematologists took center stage at the 2026 Tandem Meetings, a multidisciplinary meeting of experts in the field of blood stem cell transplantation, held in Salt Lake City ...